Gao et al. BMC Cancer 2011, 11:177 http://www.biomedcentral.com/1471-2407/11/177 phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Annals of Oncology 2009, 20:265-271. 11. Saito K, Khan K, Yu SZ, Ronson S, Rhee J, Li G, Van Echo D, Suntharalingam M, O’Malley BW Jr, Li D: The Predictive and Therapeutic Value of Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase in Capecitabine (Xeloda)-Based Chemotherapy for Head and Neck Cancer. The Laryngoscope 2009, 119:82-88. 12. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom: Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. N Engl J Med 2008, 358:36-46. 13. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanoy R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first- line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009, 20:666-673. 14. Baize N, Abakar-Mahamat A, Mounier N, Berthier F, Caroli-Bosc FX: Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. Cancer Chemother Pharmacol 2009, 64:549-55. 15. Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK: A phase II study of paclitaxel and capecitabine as a first- line combination chemotherapy for advanced gastric cancer. Br J Cancer 2008, 98:316-322. 16. Jordan MA: Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002, 2:1-17. 17. Horwitz SB, Lothstein L, Manfredi JJ, Mellado W, Parness J, ROY SN, Schiff PB, Sorbara L, Zeheb R: Taxol: mechanisms of action and resistance. Ann N Y Acad Sci 1986, 466:733-44. 18. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JTM, Fojo T, Poruchynsky MS: Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997, 272:17118-25. 19. Monzó M, Rosell R, Sánchez JJ, Lee JS, O’Brate A, González-Larriba JL, Alberola V, Lorenzo JC, Núñez L, Ro JY, Martín C: Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999, 17:1786-93. 20. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G: Class III β-Tubulin Overexpression Is a Prominent Mechanism of Paclitaxel Resistance in Ovarian Cancer Patients. Clinical Cancer Research 2005, 11:298-305. 21. Lu Q, Luduena RF: Removal of β III isotype enhances taxol induced microtubule assembly. Cell Struct Funct 1993, 18:173-82. 22. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997, 100:1282-93. 23. Sève P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A, Dumontet G: Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Molecular Cancer Therapeutics 2005, 4:2001-2007. 24. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR: Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998, 77:562-6. 25. Burkhart CA, Kavallaris M, Horwitz SB: The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001, 1471:1-9. 26. Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H: Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009, 64:326-33. 27. Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, Scambia G, Ferlini C: Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006, 12:2774-9. 28. Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, Latorre A, Schittulli F, Lorusso V: Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Annals of Oncology 2005, 16:14-19. 29. Urano N, Fujiwara Y, Hasegawa S, Miyoshi Y, Noguchi S, Takiguchi S, Yasuda T, Yano M, Monden M: Absence of beta-tubulin gene mutation in gastric carcinoma. Gastric Cancer 2003, 6:108-12. Page 8 of 8 30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 31. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S- transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Annals of Oncology 2007, 18:504-509. 32. Kolinsky K, Zhang YE, Dugan U, Heimbrook D, Packman K, Higgins B: Novel Regimens of Capecitabine Alone and Combined with Irinotecan and Bevacizumab in Colorectal Cancer Xenografts. Anticancer Research 2009, 29:91-98. 33. Sawada N, Kondoh K, Mori K: Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer Xenografts. Oncology Report 2007, 18:775-778. 34. Ishitsuka H: Capecitabine: preclinical pharmacology studies. Invest New Drugs 2000, 18:343-354. 35. Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R: Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2006, 24:4069-4077. 36. Koopman M, Venderbosch S, van Tinteren H, Ligtenberg MJ, Nagtegaal I, Van Krieken JH, Punt CJ: Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer 2009, 45:1999-2006. 37. Mozzetti S, Iantomasi R, Maria ID, Prislei S, Mariani M, Camperchioli A, Bartollino S, Gallo D, Scambia G, Ferlini C: Molecular mechanisms of patupilone resistance. Cancer research 2008, 8:10197-10204. 38. Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET, Namiki M: The Establishment of Two Paclitaxel-Resistant Prostate Cancer Cell Lines and the Mechanisms of Paclitaxel Resistance with Two Cell Lines. Prostate 2007, 67:955-967. 39. Maher JF, Villalona-Calero MA: Taxanes and capecitabine in combination: rationale and clinical results. Clin Breast Cancer 2002, 2:287-93. 40. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR: K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. The New England Journal of Medicine 2008, 359:1757-1765. 41. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA: Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor. Journal of Clinical Oncology 2003, 21:4342-4349. 42. Bai H, Mao L, Wang SH, Zhao J, Yang L, An TT, Wang X, Duan JC, Wu MN, Guo QZ, Liu XY, Liu NH, Wang YY, Wang J: Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 2009, 27:2653-2659. 43. Petit T, Borel C, Ghnassia JP, Rodier JF, Escande A, Mors R, Haeqeie P: Chemotherapy Response of Breast Cancer Depends on HER-2 Status and Anthracycline Dose Intensity in the Neoadjuvant Setting. Clinical Cancer Research 2001, 7:1577-1581. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/11/177/prepub doi:10.1186/1471-2407-11-177 Cite this article as: Gao et al.: Thymidine Phosphorylase/b-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer 2011 11:177.